Veracyte, Inc. (VCYT) Presents Breakthrough Genomic Data to Predict Cancer Therapy Response at ASCO

Veracyte, Inc. (NASDAQ:VCYT) announced that eight new studies featuring its Decipher Prostate and Decipher Bladder genomic classifiers will be presented at the ASCO 2025 annual meeting in Chicago, highlighting advances in personalized cancer care. Key findings reveal that patients with metastatic prostate cancer whose tumors display a PTEN-inactive gene expression signature benefit significantly from adding docetaxel to standard androgen deprivation therapy, with a 43% reduction in risk of death, while those with PTEN-active tumors do not see this benefit.

The Decipher Prostate test, validated in over 90 studies, continues to demonstrate its value in guiding treatment intensity and timing for prostate cancer patients.

For bladder cancer, interim results from the SURE-02 trial show that combining Sacituzumab Govitecan and Pembrolizumab as neoadjuvant therapy, followed by response-adapted bladder-sparing strategies, is both safe and effective for muscle-invasive cases. The Decipher Bladder GRID tool identified molecular subtypes associated with better clinical responses, paving the way for more targeted therapies.

These studies underscore the power of Veracyte, Inc. (NASDAQ:VCYT)’s whole-transcriptome-based GRID platform, which now includes over 200,000 urologic cancer profiles, to drive research and enable more personalized treatment decisions for prostate and bladder cancer patients.

While we acknowledge the potential of VCYT to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk.  If you are looking for an AI stock that is more promising than VCYT and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 10 Best Cancer Stocks to Invest in for Long-Term Gains and 10 Most Oversold Stocks to Buy According to Billionaires.

Disclosure: None.